TNF and inflammatory bowel disease: The morbidity of IBD is on the rise; however, current IBD therapeutic agents such as salicylazosulfapyridine (SASP), immunosuppressive agents, and anti-TNF-α monoclonal antibodies have showed limited efficacy and potential long-term toxicity [47, 48].